|
Hutchmed China Ltd on Tuesday said Chief Executive Officer Weiguo Su will take a leave of absence for health reasons. The Hong Kong-based developer of treatments for cancer and immunological diseases said it has appointed Chief Financial Officer Johnny Cheng as acting CEO with immediate effect. He will remain CFO as well. ‘The board expresses its full support for Dr Su and wishes him a speedy recovery,’ said Chair Dan Eldar. ‘The board has full confidence in Cheng’s capabilities to lead the company. The board is confident that all research, development and commercial initiatives will remain on track.’ CEO Su said, ‘This has been a very difficult decision to make, but at this time my focus must be on my health. I am certain that the board, Mr Cheng and everyone at Hutchmed will ensure the continued execution of our strategy and that the scientific team will continue its work on the determined drug research and discovery pipeline as planned. ‘I would like to thank everyone for their support and look forward to being able to return to work as soon as possible.’ Shares in Hutchmed China were down 2.1% at 231.00 pence in London on Tuesday morning. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
